XML 43 R36.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

License and Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Jan. 01, 2024 | Sep. 30, 2022 | Mar. 31, 2023 | Jul. 31, 2020 | Mar. 31, 2024 | Sep. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2020
Preferred stock, shares issued (in shares) |  |  |  |  | 0 |  |  | 0 |
Acquired IPR&D expense |  | $ 3,000 |  |  |  |  |  |  |
Quarterly fee | $ 600 |  |  |  | $ 1,300 |  |  |  |
Delivery fee |  |  |  |  | 200 |  |  |  |
Completion fee |  |  |  |  | 200 |  |  |  |
Exercise fee |  |  |  |  | $ 1,000 |  |  |  |
Accrued Upfront Fee |  |  |  |  |  |  |  |  | $ 200
Royalty Based on Net Sales of Licensed Products, Percentage |  |  |  |  | 1.00% |  |  |  |
Royalty expense |  |  |  |  | $ 0 |  |  |  |
Research and Development [Member] |  |  |  |  |  |  |  |  |
Quarterly fee |  |  |  |  | 600 |  | $ 1,300 |  |
Research Development And Regulatory Milestone |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  | 18,000 |  |  |  |
Adimab Assignment Agreement [Member] |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  | $ 11,100 |  |  | $ 11,100 |
Adimab Assignment Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  | $ 24,600 |  |  |  |  |
Royalty percentage of sublicense consideration |  |  |  |  | 55.00% |  |  |  |
Adimab Assignment Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |
Royalty percentage of sublicense consideration |  |  |  |  | 45.00% |  |  |  |
Adimab Assignment Agreement [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |
Recognized expense |  |  |  |  | $ 0 |  | 0 |  |
Adimab Assignment Agreement [Member] | Acquired In Process Research And Development Expense [Member] |  |  |  |  |  |  |  |  |
Milestone payment |  |  | $ 400 |  | 0 | $ 3,200 | 400 |  |
Adimab Assignment Agreement [Member] | First Product [Member] |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  | 16,500 |  |  |  |  |
Adimab Assignment Agreement [Member] | Second Product [Member] |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  | $ 8,100 |  |  |  |  |
Adimab Collaboration Agreement [Member] |  |  |  |  |  |  |  |  |
Expenses |  |  |  |  | 0 |  | 200 |  |
Adimab Collaboration Agreement [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |
Quarterly fee |  |  |  |  | 600 |  | 1,300 |  |
Adimab Collaboration Agreement [Member] | Acquired In Process Research And Development Expense [Member] |  |  |  |  |  |  |  |  |
Exercise fee |  |  |  |  | 0 |  | 0 |  |
Adimab Platform Transfer Agreement [Member] | Research Development And Regulatory Milestone |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  | 9,500 |  |  |  |
Cell Line License Agreement [Member] |  |  |  |  |  |  |  |  |
Acquired IPR&D expense |  |  |  |  | $ 0 |  | $ 400 |  |

X
- Definition Accrued Upfront Fee. + References No definition available. + Details
Name: | ivvd_AccruedUpfrontFee
Namespace Prefix: | ivvd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Acquired in-process research and development expense. + References No definition available. + Details
Name: | ivvd_AcquiredInProcessResearchAndDevelopmentExpense
Namespace Prefix: | ivvd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Completion Fee. + References No definition available. + Details
Name: | ivvd_CompletionFee
Namespace Prefix: | ivvd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Delivery Fee. + References No definition available. + Details
Name: | ivvd_DeliveryFee
Namespace Prefix: | ivvd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Exercise Fee. + References No definition available. + Details
Name: | ivvd_ExerciseFee
Namespace Prefix: | ivvd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | ivvd_MilestonePayment
Namespace Prefix: | ivvd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential milestone payment. + References No definition available. + Details
Name: | ivvd_PotentialMilestonePayment
Namespace Prefix: | ivvd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Quarterly Fee. + References No definition available. + Details
Name: | ivvd_QuarterlyFee
Namespace Prefix: | ivvd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty Based on Net Sales of Licensed Products, Percentage. + References No definition available. + Details
Name: | ivvd_RoyaltyBasedOnNetSalesOfLicensedProductsPercentage
Namespace Prefix: | ivvd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty, Percentage of Sublicense Consideration. + References No definition available. + Details
Name: | ivvd_RoyaltyPercentageOfSublicenseConsideration
Namespace Prefix: | ivvd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total costs of sales and operating expenses for the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_CostsAndExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_PreferredStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ivvd_ResearchDevelopmentAndRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_AdimabAssignmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=ivvd_AcquiredInProcessResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ivvd_FirstProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ivvd_SecondProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_AdimabCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_AdimabPlatformTransferAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_WuXiCellLineLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |